Abbott Laboratories $ABT is Grantham Mayo Van Otterloo & Co. LLC’s 6th Largest Position

Grantham Mayo Van Otterloo & Co. LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,814,538 shares of the healthcare product maker’s stock after selling 293,045 shares during the period. Abbott Laboratories makes up about 3.2% of Grantham Mayo Van Otterloo & Co. LLC’s portfolio, making the stock its 6th largest holding. Grantham Mayo Van Otterloo & Co. LLC owned 0.45% of Abbott Laboratories worth $1,062,855,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ABT. IMG Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares in the last quarter. Elequin Capital LP purchased a new position in Abbott Laboratories during the first quarter valued at $30,000. Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Vision Financial Markets LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at about $33,000. Finally, Accent Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $128.70 on Friday. The company’s 50-day moving average is $129.55 and its two-hundred day moving average is $131.07. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $223.80 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, meeting the consensus estimate of $1.30. The firm had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were given a $0.59 dividend. The ex-dividend date of this dividend was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Daiwa Capital Markets boosted their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Benchmark started coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 target price for the company. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Barclays increased their price objective on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a report on Friday, October 17th. Finally, Sanford C. Bernstein upped their price target on Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.